CLAIMS

1. A *N. meningitidis* conjugate vaccine for use in the prevention or treatment of *N. meningitidis* disease wherein a human patient is immunised in a schedule comprising steps a) and b) wherein:

step a) immunises the human patient at a first age of between 0 and 11 months with a bacterial saccharide conjugate vaccine comprising at least one, two or three bacterial saccharide(s) conjugated to a carrier protein to form at least one, two or three bacterial saccharide conjugate(s); and

step b) immunises the human patient at a second age of between 12 and 24 months with a *Neisseria meningitidis* conjugate vaccine comprising at least two capsular saccharides selected from the group consisting of *N. meningitidis* serogroup A capsular saccharide (MenA), *N. meningitidis* serogroup C capsular saccharide (MenC), *N. meningitidis* serogroup W135 capsular saccharide (MenW135), and *N. meningitidis* serogroup Y capsular saccharide (MenY) conjugated separately to a carrier protein, wherein the *Neisseria meningitidis* conjugate vaccine is co-administered with a vaccine comprising diphtheria toxoid and tetanus toxoid.

2. The *N. meningitidis* conjugate vaccine for use according to claim 1, wherein the at least one, two or three bacterial saccharide(s) of step a) comprises a *Haemophilus influenza* (Hib) saccharide.

3. The *N. meningitidis* conjugate vaccine for use according to claim 1 or 2, wherein the at least one, two or three bacterial saccharide(s) of step a) comprises *a N. meningitidis* serogroup C (MenC) capsular saccharide.

4. The *N. meningitidis* conjugate vaccine for use according to any one of claims 1-3, wherein the at least one, two or three bacterial saccharide(s) of step a) comprises a *N. meningitidis* serogroup Y (MenY) capsular saccharide.

5. The *N. meningitidis* conjugate vaccine for use according to any one of claims 1-4, wherein the carrier protein of step a) is tetanus toxoid, diphtheria toxoid or CRM197.

6. The *N. meningitidis* conjugate vaccine for use according to claim 5, wherein the carrier protein of step a) is tetanus toxoid, optionally at a total TT content of 5-40, 10-30, 15-20 µg or about 18µg per dose.

7. The *N. meningitidis* conjugate vaccine for use according to any one of claims 1-6, wherein the immunisation of step a) involves the administration of 2 or 3 doses of the bacterial saccharide conjugate, optionally at 2, 4 and 6 months of age.

8. The *N. meningitidis* conjugate vaccine for use according to any one of claims 1-7, wherein co-administration of the *Neisseria meningitidis* conjugate vaccine and the vaccine comprising diphtheria toxin and tetanus toxin in step b) leads to an at least 10% increase in immunogenicity against at least one of MenA, MenC, MenW135 or MenY compared to where the *Neisseria meningitidis* conjugate vaccine is administered alone, optionally measured by SBA assay.

9. The *N. meningitidis* conjugate vaccine for use according to any one of claims 1-8, wherein during step a) the bacterial saccharide conjugate vaccine is administered at the same time as a vaccine comprising DTP.

10. The *N. meningitidis* conjugate vaccine for use according to any one of claims 1-9, wherein the *N. meningitidis* conjugate vaccine of step b) comprises MenA.

11. The *N. meningitidis* conjugate vaccine for use according to any one of claims 1-10, wherein the *N. meningitidis* conjugate vaccine of step b) comprises MenC.

12. The *N. meningitidis* conjugate vaccine for use according to any one of claims 1-11, wherein the *N. meningitidis* conjugate vaccine of step b) comprises MenW135.

13. The *N. meningitidis* conjugate vaccine for use according to any one of claims 1-12, wherein the *N. meningitidis* conjugate vaccine of step b) comprises MenY.

14. The *N. meningitidis* conjugate vaccine for use according to any one of claims 1-13, wherein the carrier protein of step b) is selected from the group consisting of tetanus toxoid, diphtheria toxoid or CRM197.

15. The *N. meningitidis* conjugate vaccine for use according to any one of claims 1-14, wherein the carrier protein of step a) and the carrier protein of step b) are the same.